These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17080412)

  • 1. Influence of polymorphic form, morphology, and excipient interactions on the dissolution of carbamazepine compacts.
    Tian F; Sandler N; Aaltonen J; Lang C; Saville DJ; Gordon KC; Strachan CJ; Rantanen J; Rades T
    J Pharm Sci; 2007 Mar; 96(3):584-94. PubMed ID: 17080412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visualizing the conversion of carbamazepine in aqueous suspension with and without the presence of excipients: a single crystal study using SEM and Raman microscopy.
    Tian F; Sandler N; Gordon KC; McGoverin CM; Reay A; Strachan CJ; Saville DJ; Rades T
    Eur J Pharm Biopharm; 2006 Nov; 64(3):326-35. PubMed ID: 16846721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of coformers on phase transformation and release profiles of carbamazepine cocrystals in hydroxypropyl methylcellulose based matrix tablets.
    Qiu S; Li M
    Int J Pharm; 2015 Feb; 479(1):118-28. PubMed ID: 25542989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo evaluation of novel immediate release carbamazepine tablets: complexation with hydroxypropyl-β-cyclodextrin in the presence of HPMC.
    Kou W; Cai C; Xu S; Wang H; Liu J; Yang D; Zhang T
    Int J Pharm; 2011 May; 409(1-2):75-80. PubMed ID: 21371541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ monitoring of carbamazepine-nicotinamide cocrystal intrinsic dissolution behaviour.
    Qiao N; Wang K; Schlindwein W; Davies A; Li M
    Eur J Pharm Biopharm; 2013 Apr; 83(3):415-26. PubMed ID: 23159709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbamazepine/betaCD/HPMC solid dispersions. I. Influence of the spray-drying process and betaCD/HPMC on the drug dissolution profile.
    Koester LS; Mayorga P; Bassani VL
    Drug Dev Ind Pharm; 2003 Feb; 29(2):139-44. PubMed ID: 12648010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of intrinsic dissolution behavior of different carbamazepine samples.
    Sehić S; Betz G; Hadzidedić S; El-Arini SK; Leuenberger H
    Int J Pharm; 2010 Feb; 386(1-2):77-90. PubMed ID: 19900519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the effect of hydroxypropyl methylcellulose on the phase transformation and release profiles of carbamazepine-nicotinamide cocrystal.
    Li M; Qiu S; Lu Y; Wang K; Lai X; Rehan M
    Pharm Res; 2014 Sep; 31(9):2312-25. PubMed ID: 24590881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic differences in permeation behavior of supersaturated and solubilized solutions of carbamazepine revealed by nuclear magnetic resonance measurements.
    Ueda K; Higashi K; Limwikrant W; Sekine S; Horie T; Yamamoto K; Moribe K
    Mol Pharm; 2012 Nov; 9(11):3023-33. PubMed ID: 22970935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissolution Profiles of Carbamazepine Cocrystals with Cis-Trans Isomeric Coformers.
    Omori M; Yamamoto H; Matsui F; Sugano K
    Pharm Res; 2023 Feb; 40(2):579-591. PubMed ID: 35194718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards a universal dissolution medium for carbamazepine.
    El-Massik MA; Abdallah OY; Galal S; Daabis NA
    Drug Dev Ind Pharm; 2006 Aug; 32(7):893-905. PubMed ID: 16908426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Coformer and Polymer on Particle Surface Solution-Mediated Phase Transformation of Cocrystals in Aqueous Media.
    Omori M; Watanabe T; Uekusa T; Oki J; Inoue D; Sugano K
    Mol Pharm; 2020 Oct; 17(10):3825-3836. PubMed ID: 32870691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability in commercial carbamazepine samples--impact on drug release.
    Flicker F; Eberle VA; Betz G
    Int J Pharm; 2011 May; 410(1-2):99-106. PubMed ID: 21435386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of various excipients on the conversion kinetics of carbamazepine polymorphs in aqueous suspension.
    Tian F; Saville DJ; Gordon KC; Strachan CJ; Zeitler JA; Sandler N; Rades T
    J Pharm Pharmacol; 2007 Feb; 59(2):193-201. PubMed ID: 17270073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method.
    Sethia S; Squillante E
    J Pharm Sci; 2002 Sep; 91(9):1948-57. PubMed ID: 12210042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Simulated Gastrointestinal Fluids on Polymorphic Behavior of Anhydrous Carbamazepine Form III and Biopharmaceutical Relevance.
    Bhise SB; Rajkumar M
    PDA J Pharm Sci Technol; 2010; 64(1):28-36. PubMed ID: 21502001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucosamine HCl as a new carrier for improved dissolution behaviour: effect of grinding.
    Al-Hamidi H; Edwards AA; Mohammad MA; Nokhodchi A
    Colloids Surf B Biointerfaces; 2010 Nov; 81(1):96-109. PubMed ID: 20674291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Influence of different auxiliary materials on the dissolution of carbamazepine from solid dosage forms].
    Jeköné BZ
    Acta Pharm Hung; 1998 Mar; 68(2):133-6. PubMed ID: 9592940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph.
    Rodríguez-Hornedo N; Murphy D
    J Pharm Sci; 2004 Feb; 93(2):449-60. PubMed ID: 14705201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical stability of crystal hydrates and their anhydrates in the presence of excipients.
    Salameh AK; Taylor LS
    J Pharm Sci; 2006 Feb; 95(2):446-61. PubMed ID: 16380975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.